Immuneering Corporation announced a private placement of securities to top-tier institutional and accredited investors, expecting to raise approximately $25 million.
Updated overall survival data from their ongoing Phase 2a trial in pancreatic cancer patients showed promising results, with a 94% overall survival rate at 6 months.
The funds raised will support the development and distribution of atebimetinib, an innovative Deep Cyclic Inhibitor targeting MEK in the MAPK pathway.
Private Placement
Approximately $25 million raised through a securities purchase agreement with institutional investors.
Clinical Trial Progress
Positive 6-month overall survival data from the Phase 2a trial in pancreatic cancer patients.
Deep Cyclic Inhibitors
Focus on developing a new category of cancer medicines targeting MEK in the MAPK pathway.
- The private placement signifies investor confidence in Immuneering's innovative approach to oncology treatments.
- Positive trial results boost the company's position in the competitive oncology market, attracting interest from pharmaceutical companies and investors.
Immuneering's successful private placement and promising clinical trial data highlight the potential of their innovative cancer treatment approach.